2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

GC cells

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

7

Peptides

2

Inhibitory Antibodies

2

Natural
Products

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-149453
    MCUF-651

    		Guanylate Cyclase Cardiovascular Disease
    MCUF-651 is an orally active guanylyl cyclase A receptor (GC-A) positive allosteric modulator (PAM) (KD: 397 nM ). MCUF-651 binds to GC-A and selectively enhances the binding of atrial natriuretic peptide (ANP) to GC-A. MCUF-651 enhances ANP-mediated cGMP generation in human cardiac, renal, and fat cells. MCUF-651 inhibits cardiomyocyte hypertrophy .
    MCUF-651
  • HY-108741
    Plecanatide

    		Guanylate Cyclase Inflammation/Immunology Cancer
    Plecanatide, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide activates GC-C receptors to stimulate cGMP synthesis with an EC50 of 190 nM in T84 cells assay. Plecanatide shows anti-inflammatory activity in models of murine colitis .
    Plecanatide
  • HY-114043
    NCGC00092410

    		Glycosidase Metabolic Disease
    NCGC00092410 is a potent, selective, and nonsugar glucocerebrosidase (GC) inhibitor, with an IC50 of 31 nM. NCGC00092410 shows no activity against the related hydrolases at concentrations up to 77 μM. NCGC00092410, a GC chaperone, and increases the activity and lysosomal localization of glucocerebrosidase in mutant cell lines. NCGC00092410 can be used for the research of Gaucher disease .
    NCGC00092410
  • HY-108741A
    Plecanatide acetate

    		Guanylate Cyclase Inflammation/Immunology Cancer
    Plecanatide acetate, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide acetate activates GC-C receptors to stimulate cGMP synthesis with an EC50 of 190 nM in T84 cells assay. Plecanatide acetate can be used for the research of chronic idiopathic constipation, and it also shows anti-inflammatory activity in models of murine colitis .
    Plecanatide acetate
  • HY-136684
    BrBzGCp2
    3 Publications Verification

    S-p-Bromobenzylglutathione cyclopentyl diester

    		 Glyoxalase (GLO) Neurological Disease Cancer
    BrBzGCp2 is a Glyoxalase 1 (GLO1) inhibitor, with a GC50 of 4.23 μM in HL-60 cells. BrBzGCp2 possesses antitumor and neuroprotective activity .
    BrBzGCp2
  • HY-111798A
    Heme Oxygenase-1-IN-1 hydrochloride
    5+ Cited Publications

    		 Reactive Oxygen Species Cancer
    Heme Oxygenase-1-IN-1 (Compound 2) hydrochloride is a heme oxygenase 1 (HO-1) inhibitor with an IC50 of 0.25 μM .
    Heme Oxygenase-1-IN-1 hydrochloride
  • HY-111798
    Heme Oxygenase-1-IN-1
    5+ Cited Publications

    		 Reactive Oxygen Species Cancer
    Heme Oxygenase-1-IN-1 (compound 2) is a potent heme oxygenase 1 (HO-1) inhibitor, with an IC50 of 0.25 μM. Heme Oxygenase-1-IN-1 can be used for cancer research .
    Heme Oxygenase-1-IN-1
  • HY-131389
    Cholesteryl heptadecanoate

    		Biochemical Assay Reagents Others
    Cholesteryl heptadecanoate is a cholesteryl ester internal standard that accurately determines the concentration of free cholesterol in cells without hydrolyzing triglycerides. Cholesteryl heptadecanoate can be used for the quantitative determination of cholesteryl esters by GC or LC mass spectrometry .
    Cholesteryl heptadecanoate
  • HY-162293
    CDK8-IN-14

    		CDK Cancer
    CDK8-IN-14 (compound 12) inhibits CDK8 with an IC50 value of 39.2 nM and has anti-AML cell proliferation activity (molm-13 GC50 = 0.02±0.01μM, MV4-11 GC50 = 0.03±0.01μM) .
    CDK8-IN-14
  • HY-156020
    Glucocerebrosidase-IN-2

    		Glycosidase Metabolic Disease
    Glucocerebrosidase-IN-2 (compound 12) is a quinazoline analogue and an inhibitor of glucocerebrosidase (GC). Glucocerebrosidase-IN-2 has the potential to improve GC translocation to lysosomes in Gaucher disease patient-derived cells (mostly carrying the N370S mutation). Glucocerebrosidase-IN-2 inhibits the hydrolysis of 4-methylumbelliferone β-D-glucopyranoside (4MU) and fluorescent glycosylceramide (FlourGC) in N370S mutant tissues with an AC50 of 25.29 μM .
    Glucocerebrosidase-IN-2
  • HY-10498
    Lexibulin
    2 Publications Verification

    CYT-997

    		 Microtubule/Tubulin Reactive Oxygen Species Apoptosis Cancer
    Lexibulin (CYT-997) is a potent and orally active tubulin polymerisation inhibitor with IC50s of 10-100 nM in cancer cell lines; with potent cytotoxic and vascular disrupting activity in vitro and in vivo . Lexibulin induces cell apoptosis and induces mitochondrial ROS generation in GC cells .
    Lexibulin
  • HY-10498A
    Lexibulin dihydrochloride

    CYT-997 dihydrochloride

    		 Microtubule/Tubulin Reactive Oxygen Species Apoptosis Cancer
    Lexibulin dihydrochloride (CYT-997 dihydrochloride) is a potent and orally active tubulin polymerisation inhibitor with IC50s of 10-100 nM in cancer cell lines; with potent cytotoxic and vascular disrupting activity in vitro and in vivo . Lexibulin dihydrochloride induces cell apoptosis and induces mitochondrial ROS generation in GC cells .
    Lexibulin dihydrochloride
  • HY-P0118A
    Disitertide TFA

    P144 TFA

    		 TGF-beta/Smad PI3K Apoptosis Cancer
    Disitertide (P144) TFA is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide TFA is also a PI3K inhibitor and an apoptosis inducer .
    Disitertide TFA
  • HY-P0118B
    Disitertide diammonium
    Maximum Cited Publications
    14 Publications Verification

    P144 diammonium

    		 TGF-beta/Smad PI3K Apoptosis Cancer
    Disitertide (P144) diammonium is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide diammonium is also a PI3K inhibitor and an apoptosis inducer .
    Disitertide diammonium
  • HY-P0118
    Disitertide

    P144

    		 TGF-beta/Smad PI3K Apoptosis Cancer
    Disitertide (P144) is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide (P144) is also a PI3K inhibitor and an apoptosis inducer .
    Disitertide
  • HY-111208
    CCT129957

    		Phospholipase Cancer
    CCT129957 is an indole derivative and a potent phospholipase C-γ (PLC-γ) inhibitor with an IC50 of ~3 μM and a GC50 of 15 μM. CCT129957 inhibits Ca 2+ release in squamous carcinoma cells at ~15 μM .
    CCT129957
  • HY-W127512
    5β-Cholanic acid

    		Drug Intermediate Others
    5β-Cholanic acid is a hydrophobic modifier used to modify polymer carriers. 5β-Cholanic acid can improve the acid stability, cell penetration efficiency and drug sustained release ability of nanocarriers, and optimize the oral effectiveness of delivered molecules. 5β-Cholanic acid can covalently bind to Glycol chitosan (GC) to form a GC-CA conjugate, which optimizes the hydrophobic anchoring ability of nanoparticles and enables them to be stably adsorbed on the surface of PLGA nanoparticles. Such nanoparticles can resist dissociation in the gastric acid environment and maintain positive charge to enhance endocytic uptake by intestinal epithelial cells (such as Caco-2 cells). 5β-Cholanic acid can be used in the development of drug delivery systems .
    5β-Cholanic acid
  • HY-10498R
    Lexibulin (Standard)

    CYT-997 (Standard)

    		 Microtubule/Tubulin Reactive Oxygen Species Apoptosis Cancer
    Lexibulin (Standard) is the analytical standard of Lexibulin. This product is intended for research and analytical applications. Lexibulin (CYT-997) is a potent and orally active tubulin polymerisation inhibitor with IC50s of 10-100 nM in cancer cell lines; with potent cytotoxic and vascular disrupting activity in vitro and in vivo . Lexibulin induces cell apoptosis and induces mitochondrial ROS generation in GC cells .
    Lexibulin (Standard)
  • HY-114577
    Palifosfamide tromethamine

    Isophosphoramide mustard tromethamine; IPM tromethamine; ZIO-201 tromethamine

    		 DNA Alkylator/Crosslinker Cancer
    Palifosfamide (tromethamine) is a synthetic alkylating agent with potential antineoplastic activity. As the stabilized active metabolite of ifosfamide, palifosfamide (tromethamine) irreversibly alkylates and crosslinks DNA through GC base pairs. This leads to an inhibition of DNA replication and ultimately cell death. Compared to ifosfamide, palifosfamide (tromethamine) is less toxic.
    Palifosfamide tromethamine
  • HY-19345
    Vacquinol-1

    NSC13316

    		 p38 MAPK Cancer
    Vacquinol-1 (NSC13316) is a MKK4-specific activator that activates MAPK pathways . Vacquinol-1 specifically induces human glioblastoma cell (GC) death, attenuates tumor progression and prolongs survival in a glioblastoma multiforme (GBM) mouse model . Vacquinol-1 also induces apoptosis in hepatocellular carcinoma (HCC)cell .
    Vacquinol-1
  • HY-19345A
    Vacquinol-1 dihydrochloride

    NSC13316 dihydrochloride

    		 p38 MAPK Cancer
    Vacquinol-1 (NSC13316) dihydrochloride is a MKK4-specific activator that activates MAPK pathways . Vacquinol-1 dihydrochloride specifically induces human glioblastoma cell (GC) death, attenuates tumor progression and prolongs survival in a glioblastoma multiforme (GBM) mouse model . Vacquinol-1 dihydrochloride also induces apoptosis in hepatocellular carcinoma (HCC)cell .
    Vacquinol-1 dihydrochloride
  • HY-P99013
    Codrituzumab
    1 Publications Verification

    GC33; RO5137382

    		 Glycoprotein VI Cancer
    Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .
    Codrituzumab
  • HY-P991482
    ADI-42898

    		Influenza Virus Infection
    ADI-42898 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-42898 binds to the Gn/Gc complex and blocks the cell entry of seven HCPS- and HFRS-associated hantaviruses. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    ADI-42898
  • HY-108628
    SU16f
    2 Publications Verification

    		 PDGFR Cancer
    SU16f is a potent and selective PDGFRβ inhibitor with IC50s of 10 nM, 140 nM, 2.29 μM for PDGFRβ, VEGF-R2, FGF-R1, respectively . Neutralization of PDGFRβ receptor by SU16f blocks the promoting role of GC-MSCs (gastric cancer-derived mesenchymal stem cells) conditioned medium in gastric cancer cell proliferation and migration .
    SU16f
  • HY-W040129
    Chromomycin A3
    1 Publications Verification

    		 DNA Alkylator/Crosslinker DNA/RNA Synthesis Apoptosis Caspase Infection Neurological Disease Cancer
    Chromomycin A3 is an inhibitor that selectively binds to GC-rich DNA sequences. Chromomycin A3 targets the DNA minor groove after forming a dimer with Mg 2+. Chromomycin A3 inhibits DNA replication and transcription, blocks the binding of Sp1 transcription factor to target gene promoters, downregulates the expression of anti-apoptotic proteins such as FLIP, Mcl-1, and XIAP, and induces S-phase cycle arrest and caspase-dependent apoptosis in tumor cells. Chromomycin A3 can antagonize oxidative stress induced by glutathione depletion and neuronal apoptosis induced by Camptothecin (HY-15660). Chromomycin A3 can be used in basic research on malignant tumors such as cholangiocarcinoma, and is a potential chemosensitizer and GC-rich region probe .
    Chromomycin A3
  • HY-P10090
    Apoptin-derived peptide

    		Akt PI3K Apoptosis Cancer
    Apoptin-derived peptide is an antitumor polypeptide with cytotoxicity. Apoptin-derived peptide promotes apoptosis and necrosis of gastric cancer (GC) cells by regulating PI3K/AKT/ARNT signaling. Apoptin-derived peptide inhibited the invasion and migration of cancer cells, and inhibited the expression and phosphorylation of the subunit p85 of PI3K, which further inhibited the PI3K/AKT pathway involved in the development of gastric cancer .
    Apoptin-derived peptide
  • HY-W040129R
    Chromomycin A3 (Standard)

    		Bacterial Fungal Apoptosis Antibiotic Infection Neurological Disease Cancer
    Chromomycin A3 (Standard) is the analytical standard of Chromomycin A3 (HY-W040129). This product is intended for research and analytical applications. Chromomycin A3 is an inhibitor that selectively binds to GC-rich DNA sequences. Chromomycin A3 targets the DNA minor groove after forming a dimer with Mg 2+. Chromomycin A3 inhibits DNA replication and transcription, blocks the binding of Sp1 transcription factor to target gene promoters, downregulates the expression of anti-apoptotic proteins such as FLIP, Mcl-1, and XIAP, and induces S-phase cycle arrest and caspase-dependent apoptosis in tumor cells. Chromomycin A3 can antagonize oxidative stress induced by glutathione depletion and neuronal apoptosis induced by Camptothecin (HY-15660). Chromomycin A3 can be used in basic research on malignant tumors such as cholangiocarcinoma, and is a potential chemosensitizer and GC-rich region probe .
    Chromomycin A3 (Standard)
  • HY-146398
    AMPK activator 6

    		AMPK Metabolic Disease
    AMPK activator 6 (Compound GC) reduces lipid content and activates the AMPK pathway in HepG2 and 3T3-L1 cells. AMPK activator 6 significantly suppresses the increase in triglyceride (TG) , total cholesterol (TC), low-density lipoprotein-C (LDL-C), and other biochemical indices in blood serum. AMPK activator 6 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome .
    AMPK activator 6
  • HY-P10786
    LinTT1 peptide

    		Transmembrane Glycoprotein Cancer
    LinTT1 peptide is a tumor-penetrating peptide with the amino acid sequence AKRGARST. LinTT1 peptide targets peritoneal carcinoma (PC) by binding to the p32 (gC1qR) receptor. It can conjugate with iron oxide nanoworms (NWs) to form a nanocarrier. This nanocarrier is taken up by peritoneal carcinoma cells in vitro and enters the mitochondria; it also exhibits significant tumor targeting and penetration effects in mice. Moreover, LinTT1-functionalized nanocarriers, combined with the pro-apoptotic peptide [D(KLAKLAK)2], show significant tumor suppression in a mouse peritoneal tumor model. LinTT1 peptide holds promise as a delivery carrier for peritoneal cancer research .
    LinTT1 peptide
  • HY-132184
    5,6-Epoxyeicosatrienoic acid

    5,6-EET; (±)5,6-EpETrE

    		 Adrenergic Receptor Calcium Channel Endocrinology
    5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC50=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2.
    5,6-Epoxyeicosatrienoic acid
  • HY-132184S
    5,6-Epoxyeicosatrienoic acid-d11

    5,6-EET-d11; (±)5,6-EpETrE-d11

    		 Isotope-Labeled Compounds Adrenergic Receptor Endocrinology
    5,6-Epoxyeicosatrienoic acid-d11 (5,6-EET-d11) is deuterium labeled 5,6-Epoxyeicosatrienoic acid. 5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC50=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2, as measured by oxygen consumption and product formation assays when used at a concentration of 50 μM. (±)5,6-Epoxyeicosatrienoic acid is provided as a mixture of the free acid and lactone .
    5,6-Epoxyeicosatrienoic acid-d11

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: